biopharmaceutical

Madison Carter is a fearless investigative reporter. She takes no day for granted because she lives with type 1 diabetes (T1D). Dr. Doug Melton is a world-renowned stem cell researcher and distinguished fellow at Vertex – and his now grown children, Sam and Emma, live with T1D. Along with scientists like Dr. Felicia Pagliuca, who leads Vertex’s research into T1D, he’s been on a quest to help Madison, Sam, Emma, and others like them by investigating the disease at a cellular level. 

Produced by Bloomberg Media Studios and Vertex Pharmaceuticals. 

Featured guests:

Madison Carter is an investigative journalist with 11Alive News, an NBC affiliate in Atlanta, GA. She's living with type 1 diabetes. 

Aaron Kowalski is the President and CEO of JDRF. 

Felicia Pagliuca is the Disease Area Executive, Type 1 Diabetes, at Vertex Pharmaceuticals

Doug Melton leads investigations into treatments for Type 1 Diabetes at Vertex Pharmaceuticals. He is renowned for his stem cell research at Harvard University. Read more about Vertex's approach to targeting type 1 diabetes

Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.

NBA great Alonzo Mourning returned home from the Sydney Olympics after winning the gold medal feeling ill. He surprisingly was diagnosed shortly after with kidney disease. Scientists have discovered his type of kidney disease is linked to having genetic variants of the APOL1 gene – ones that 13% of people with African ancestry carry. Dr. Ogo Egbuna leads clinical development for the team researching APOL1-mediated kidney disease at Vertex where they’re investigating a small molecule therapy to target its underlying cause.

Produced by Bloomberg Media Studios and Vertex Pharmaceuticals. 
 

Featured guests:

Alonzo Mourning is a retired NBA player, the Vice President, Player Programs for the Miami Heat, an advocate for kidney disease research, and a beneficiary of a kidney transplant.

David Friedman is an Associate Professor of Medicine, Harvard Medical School and a Principal Investigator and Nephrologist at Beth Israel Deaconess Medical Center. He's researched and consulted for Vertex Pharmaceuticals.

Janice Lea  is a Professor of Medicine and Clinical Director of Nephrology at Emory University School of Medicine.

Ogo Egbuna is Vice President, Clinical Development at Vertex Pharmaceuticals Read more about Vertex's approach to targeting kidney disease.

Produced by Bloomberg Media Studios and Vertex Pharmaceuticals. 
 

Today on The Alden Report, I welcome Doug Drysdale who is attempting to revolutionize the treatment of mental health disorders and addictions by developing novel therapies using psychedelics. An experienced Corporate Director and CEO, Doug has chaired the board of directors of a NASDAQ-listed company and has built and turned-around three pharmaceutical companies as CEO over the last 12 years. During Doug’s 30 plus years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 15 corporate acquisitions across three continents and has raised $4 billion of both public and private capital. He was also recognized as Entrepreneur of the Year by Ernst and Young in 2012. 

Currently, Doug is the CEO of Cybin which is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally-recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

This is a fascinating discussion that you’re not going to want to miss. We even discuss Cybin’s popularity with individuals such as Tony Robbins and Deepak Chopra. 

Thank you very much to Doug Drysdale for joining us this week on The Alden Report. 

For more information on Doug and his company, you can visit: https://cybin.com/ 

Thank you to this episode's sponsor:

Wicked Happy – Apparel To Make You Smile
The way we live our lives depends on our outlook. Wicked Happy designs apparel to make people smile because they want to make you Wicked Happy.

Use code MIKEALDEN at checkout for 15% off of your first order.

www.wickedhappy.com

For more info on Michael Alden visit: https://www.mikealden.com/

For more info on Michael Alden’s latest book BEST SELLER SECRETS visit: https://www.bestsellersecretsbook.com/

Listen to other episodes of The Alden Report here: https://thealdenreport.com/

Follow Mike Alden here:

Facebook: https://www.facebook.com/MikeAlden2012

Twitter: https://twitter.com/MikeAlden2012

Instagram: https://www.instagram.com/mikealden

TikToK: https://www.tiktok.com/@mikealden2012

DLA Piper's Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky, founding Partner and Portfolio Manager at RA Capital, to discuss the importance of – and complications in – balancing biopharmaceutical innovation, industry regulations and prescription drug availability.

See omnystudio.com/listener for privacy information.

In this week’s episode, we focus on Intermountain Healthcare’s announcement that it has formed a “comprehensive health platform company focused on elevating value-based care capabilities.” The new organization, named Castell, will be led by Rajesh Shrestha as president and CEO. Shrestha will continue to serve as vice president and chief operating officer of Community Based Care for Intermountain.

Other briefs include:

• Gilead Sciences’ research and development collaboration with Belgian biopharmaceutical company Galapagos NV, valued at more than $5 billion.
• Genentech’s recent spate of research agreements.
• John Muir Health is forming “a comprehensive relationship” with Optum.
• The closing of Michigan’s Together Health Network.
• Physician participation in CMS’ Advanced Alternative Payment Models doubles in 2018.
• Care New England withdraws from merger discussions with Lifespan and Brown University.
• Memorial Hermann names Dr. David Callender as its new president and CEO, effective September 1.

About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.